Xiong Zuquan, Ma Anlun, Chen Huifang
Laboratory of Experimental Surgery, Department of Surgery, Research Centre, Centre hospitalier de l'Université de Montréal (CHUM), Hôpital Notre-Dame, and Université de Montréal, Montreal, Quebec, Canada.
Recent Pat Inflamm Allergy Drug Discov. 2010 Jan;4(1):75-81. doi: 10.2174/187221310789895577.
Janus kinase 3 (JAK3) is a cytoplasmic tyrosine kinase associated with the common gamma chain that is activated by multiple T-cell growth factors including IL-2, -4, -9, -15, and -21. From the recent reports, genetic absence or ablation of JAK3 is associated with defective T-cell immunity that results in severe combined immunodeficiency (SCID) and pharmacological inhibition has prolonged allograft survival in some models of organ transplantation. This review would provide an overview of some patents along with the role of JAK3 in the immune system and efficacy of JAK3 inhibitors in experimental allograft rejection and autoimmune disease.
Janus激酶3（JAK3）是一种与共同γ链相关的细胞质酪氨酸激酶，可被多种T细胞生长因子激活，包括白细胞介素-2、-4、-9、-15和-21。根据最近的报道，JAK3基因缺失或功能缺失与T细胞免疫缺陷有关，会导致严重联合免疫缺陷（SCID），并且在某些器官移植模型中，药物抑制可延长同种异体移植物的存活时间。本文综述将概述一些专利，以及JAK3在免疫系统中的作用，和JAK3抑制剂在实验性同种异体移植排斥反应及自身免疫性疾病中的疗效。
